18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma

被引:0
|
作者
Luo, Zhe-Huang [1 ]
Luo, Xiao-Yan [2 ]
Qi, Wan-Ling [1 ]
Liu, Qian [3 ]
机构
[1] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Dept Nucl Med, Nanchang, Peoples R China
[2] Jiangxi Prov Childrens Hosp, Affiliated Childrens Hosp, Dept Clin Lab, Nanchang Med Coll, Nanchang, Peoples R China
[3] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Dept Pathol, Nanchang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
pulmonary sarcomatoid carcinoma; fluorodeoxyglucose; positron emission tomography/computed tomography; imaging features; TTF-1; expression; RESECTION;
D O I
10.3389/fonc.2024.1334156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
<bold>Background:</bold> Pulmonary sarcomatoid carcinoma (PSC) is a rare highly aggressive and poorly differentiated non-small cell carcinoma, and little is known about the information on the usefulness of F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT). We investigated the clinical and F-18-FDG PET/CT features of PSC. <bold>Methods:</bold> We retrospectively analyzed 25 consecutive PSC patients who had undergone F-18-FDG PET/CT. Demographic data, PET/CT findings before treatment, pathological features, and prognosis in these patients were investigated to define correlates between maximal standard uptake value (SUVmax) and clinicopathological parameters. <bold>Results:</bold> From March 2017 to January 2023, twenty-five eligible patients with PSC were identified. There were 23 (92%) men, aged 68.5 +/- 8.5 (range 56-90) years. Eighteen (72%) patients had a frequent smoking history. The mean size of PSCs was 59.3 +/- 18.6 (range 29-97) mm, and 23 (92%) PSCs were Stage IV tumors. 20 (80%) lesions were located in the upper lung and 19 (76%) cases belonged to the peripheral type. Necrotic foci appeared in 21(84%) tumors. 11 (44%) PSCs invaded the pleura. All PSCs were FDG avid, and the mean of SUVmax was 11.8 +/- 5.3 (range 4.8-25.5). Metastases were found on PET/CT in 24(96%) patients. The SUVmax of the lesions >= 5cm was higher than that of the lesions < 5cm (p=0.004), and the SUVmax of lesions with TTF-1 expression was higher than those of lesions without TTF-1 expression (p=0.009). All of the 25 primary lesions were considered malignant and confirmative, probable, and possible diagnosis of PSC was made in 2 (8%), 4 (16%), and 5(20%) patients, respectively on PET/CT. PSC was not considered in 14 (56%) patients, in PET/CT. The survival of patients with surgery didn't demonstrate a significantly good prognosis as compared with those without surgery (p=0.675). <bold>Conclusion:</bold> All PSCs had obvious FDG avidity. Although imaging diagnosis is still difficult, combined clinical and imaging features more than 40% of primary lesions were considered for the possibility of PSC in our group. Early histopathological diagnosis is necessary to help develop a reasonable regimen.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] 18F-FDG PET/CT of Transitional Cell Carcinoma
    Patil, Vivek V.
    Wang, Zhen J.
    Sollitto, Richard A.
    Chuang, Kai-Wen
    Konety, Badrinath R.
    Hawkins, Randy A.
    Coakley, Fergus V.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (06) : W497 - W504
  • [32] 18F-FDG PET/CT in Metastatic Pilomatrix Carcinoma
    Vadrucci, Manuela
    Gilardi, Laura
    Crivelli, Filippo
    Baroli, Alberto
    Lomuscio, Giuseppe
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (12) : E525 - E526
  • [33] 18F-FDG PET/CT IN DIFFERENTIATED THYROID CARCINOMA
    Larg, M. I.
    Barbus, E.
    Gabora, K.
    Pestean, C.
    Cheptea, M.
    Piciu, D.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2019, 15 (02) : 203 - 208
  • [34] 18F-FDG PET/CT in the evaluation of ovarian carcinoma
    Rusu, G.
    Olariu, E.
    Alexiev, A.
    Hitu, L.
    Spinu, E.
    Gabora, K.
    Achimas-Cadariu, P.
    Piciu, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S475 - S476
  • [35] 18F-FDG PET/CT in Oral Cuniculatum Carcinoma
    Dejust, Sebastien
    El Farsaoui, Khadija
    Bellefqih, Sara
    Lalire, Paul
    Morland, David
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 741 - 742
  • [36] Usefulness of 18F-FDG PET/CT in thyroid carcinoma
    Muros de Fuentes, M. A.
    Mitjavila Casanovas, M.
    Estorch Cabrera, M.
    Lecumberri Santamaria, B.
    Navarro Gonzalez, E.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (03): : 186 - 192
  • [37] The value of 18F-FDG PET/CT in pancreatic carcinoma
    Wei, Gonghua
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [38] 18F-FDG PET/CT and Merkel Cell Carcinoma
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (08) : 25N - 25N
  • [39] Imaging in myositis: MRI or 18F-FDG PET/CT?
    Ilgen, Ufuk
    Emmungil, Hakan
    CLINICAL RHEUMATOLOGY, 2022, 41 (07) : 2253 - 2254
  • [40] PET/CT imaging with 18F-FDG in Castleman disease
    Delgado, A.
    Mesa, J.
    Guayambuco, S.
    Rodriguez, T.
    Fernandez, I.
    Rodeno, E.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (03): : 200 - 201